No Detail Found!

Mean changes in intraocular pressure after intravitreal injection of bevacizumab in exudative age related deneration and proliferative diabetic retinopathy.

Author(s)
Rebecca Isra University Hospital,Hyderabad, Pakistan
Shafi Muhammad Jatoi Isra University Hospital,Hyderabad, Pakistan
Fahad Feroz Shaikh Isra University Hospital,Hyderabad, Pakistan
Muhammad Shahid Armed Forces Institute of Ophthalmology/National University of Medical Sciences (NUMS) Rawalpindi, Pakistan
Abstract
Objective: To monitor the effect of intravit real injection of Bevacizumab on intraocular pressure to know whether intraocular pressure-lowering medication or paracentesis is required prophylactically or after that. Study Design: Case series. Place and Duration of Study: Department of Ophthalmology, Isra University Hospital, Hyderabad, from May to Oct 2019. Methodology: A total 90 eyes of patients with proliferative diabetic retinopathy and exudative age-related macular degeneration, received intravitreal injection of Bevacizumab. Intraocular pressure was recorded with a Goldman applantaion tonometer at baseline, and then after a procedure at 5 minutes, 30 minutes, 1 hour and 1 week. The patients' age, gender, disease, intraocular pressure, history of glaucoma, previous surgery, phakic status, topical and systemic medications were recorded. Results: The mean baseline intraocular pressure was 13.54 ± 2.1mmHg in proliferative diabetic retinopathy and 12.76 ± 1.8mmHg in exudative age-related macular degeneration (p-value 0.091). The mean intraocular pressure elevation following intravitreal Bevacizumab at 5 minutes was 32.89 ± 6.3mmHg and 32.18 ± 5.7mmHg (p-value 0.592), at 30 minutes was 16.71 ± 2.6mmHg and 15.53 ± 2.4mmHg (p-value 0.036), at one hour was 14.20 ± 2.0mmHg and 13.47 ± 1.9mmHg (p-value 0.098) and at one week 13.82 ± 1.7mmHg and 13.06 ± 1.7mmHg (p-value 0.051) in proliferative diabetic retinopathy and exudative agerelated macular degeneration respectively. There was no significant difference between the two diseases. Conclusion: There is an abrupt and transient rise in the intraocular pressure following intravitreal injection of Bevacizumab, but it did not remain elevated for longer duration; hence there was no need for intraocular pressure lowering medication and paracentesis.
Publication Details
Page(s) 564-567
Published Journal: Pakistan Armed Forces Medical Journal, Volume: 72, Issue: 2, Year: 2022

Request the full text from PASTIC

Keywords
Bevacizumab, Intraocular Pressure, Proliferative diabetic retinopathy, Age-related macular degeneration, Intravitreal injection
0

Citations

0

Downloads

70

Views